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Abstract
S100A4, a member of the S100 calcium-binding protein family secreted by tumor and stromal cells, supports tumorigenesis
by stimulating angiogenesis. We demonstrated that S100A4 synergizes with vascular endothelial growth factor (VEGF), via
the RAGE receptor, in promoting endothelial cell migration by increasing KDR expression and MMP-9 activity. In vivo
overexpression of S100A4 led to a significant increase in tumor growth and vascularization in a human melanoma xenograft
M21 model. Conversely, when silencing S100A4 by shRNA technology, a dramatic decrease in tumor development of the
pancreatic MiaPACA-2 cell line was observed. Based on these results we developed 5C3, a neutralizing monoclonal antibody
against S100A4. This antibody abolished endothelial cell migration, tumor growth and angiogenesis in immunodeficient
mouse xenograft models of MiaPACA-2 and M21-S100A4 cells. It is concluded that extracellular S100A4 inhibition is an
attractive approach for the treatment of human cancer.
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Introduction
Angiogenesis is a crucial multi-step process in tumor growth,
disease progression, and metastasis, where an orderly activation of
genes controlling proliferation, invasion, migration and survival of
endothelial cells (EC) participate, forming the angiogenic cascade
[1,2].
In the last decades, the active research in this field led to the
development of regulatory approvals through the blockade of
pathways related to VEGF, providing an effective therapeutic
demonstration of the proof of concept in certain types of cancer
[3,4,5]. According to clinical data these therapies have not
produced enduring efficacy in tumor reduction or long-term
survival, due to an emergent resistance to the antiangiogenic
therapy [6,7]. However, this limitation opens a new challenge for
the knowledge and identification of other main factors involved in
tumor angiogenesis to develop agents targeting multiple proangio-
genic pathways [8,9].
The S100 protein family, one of the largest subfamily of EF-
hand calcium binding proteins, is expressed in a cell and tissue
specific manner and exerts a broad range of intracellular and
extracellular functions. Its members interact with specific target
proteins involved in a variety of cellular processes, such as cell
cycle regulation, cell growth, differentiation, motility and invasion,
thus showing a strong association with some types of cancer
[10,11]. Extracellular roles for S100 members (S100B, S100A2,
S100A8, S100A9, S100A12, S100P) and for S100A4 have been
reported and are closely associated with tumor invasion and
metastasis [12,13].
Intracellular S100A4 is involved in: i) the motility and the
metastatic capacity of cancer cells, interacting with cytoskeletal
components such as the heavy chain of non-muscle myosin; ii) cell
adhesion and detachment by interaction with cadherins; iii)
remodeling of the extracellular matrix (ECM) by interaction with
matrix metalloproteinases (MMPs), and iv) cell proliferation
through its binding and sequestration of the tumor-suppressor
protein p53 [10,14,15].
S100A4 secreted by tumor and stromal cell (macrophages,
fibroblasts, and activated lymphocytes into the tumor microenvi-
ronment) is a key player in promoting metastasis; it alters the
metastatic potential of cancer cells, acting as an angiogenic factor
inducing cell motility, and increasing the expression of MMPs
[9,16,17]. Therefore, S100A4 becomes a promising target for
therapeutic applications by blocking angiogenesis and tumor
progression.
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S100A4 overexpression is strongly associated with tumor
aggressiveness and it is correlated with poor survival prognosis in
many different cancer types such as invasive pancreatic, colorectal,
prostate, breast, esophageal, gastric, and hepatocellular cancer
among others [18,19,20]. These observations suggest that S100A4
is an essential mediator of metastasis and it is a useful prognostic
marker in cancer. Even though many of the biological effects have
been described, the mechanisms by which S100A4 exerts these
effects are not completely understood.
The purpose of the present study was to investigate the cellular
mechanism of action of S100A4 in EC to better understand the
characteristics, function and therapeutic applicability of this
protein in the angiogenic process and tumor development. We
also investigated its possible cooperation with known angiogenic
factors and its implication in vivo in tumor development. We also
sought to provide the preclinical proof of principle using an anti-
S100A4 neutralizing monoclonal antibody developed in our
laboratory.
Materials and Methods
Ethical Animal Procedures
All procedures involving experimental animals were approved
by the ‘‘Ethical Committee of Animal Experimentation’’ of the
animal facility place at Science Park of Barcelona (Platform of
Applied Research in Animal Laboratory). Once approved by the
Institutional ethical committee, these procedures were additionally
approved by the ethical committee of the Catalonian authorities
according to the Catalonian and Spanish regulatory laws and
guidelines governing experimental animal care: Subcutaneous
tumor xenograft procedure (Permit number DMHA-6038); Mouse
immunization procedure (Permit number DMHA-4132).
Along the procedures using experimental animals, there was
established a continuous supervision control of the animals that
evaluated the degree of suffering of the animals and if it was the
case to sacrifice them according to the defined end point criteria
[21]. The euthanasia applied was by CO2 saturated atmosphere.
Production of Human Recombinant S100A4
To generate the S100A4 recombinant protein, a cDNA
encoding the full-length sequence of human S100A4 was obtained
by RT-PCR from mRNA of the HCT-116 cell line, derived from
human colon adenocarcinoma.
The primers used in the PCR reaction were 59-actcaca-
tatggcgtgccctctggagaaggccctggatgtg-39 and 59-actcatgagctcat-
catttcttcctgggctgcttatctgggaa-39. The S100A4 sequence was cloned into
the NdeI site of the bacterial expression vector pET28a(+)
(Novagen). Positive clones were selected and confirmed by DNA
sequencing. This construct was transformed into E.coli TunerTM
(DE3) Competent Cells (Novagen), and the protein was induced
with 1 mM isopropyl-D-thiogalacto-pyranoside (IPTG; Sigma) for
6 h. Then, bacteria were harvested and lysed by sonication (2 min.
at 30% amplitude and 4uC with pulses of 0.5 sec.) in buffer A
(100 mg/mL lysozyme, 0.5 M NaCl, 10 mM Na2HPO4.2H2O,
10 mM NaH2PO4.2H2O and 10 mM imidazole, pH 7.5). The
lysate was cleared by centrifugation and filtered through a
HisTrapTM Chelating affinity column (Amersham). The purity
of the supernatant containing the recombinant S100A4 protein
was checked by SDS-12% (w/v) polyacrylamide gel electropho-
resis.
Monoclonal Antibody Obtention
Monoclonal antibody fusion, ELISA screening and subcloning
were performed using standard technologies [22]. Maintenance,
expansion and scaling up of cell cultures were carried out in a
humidified atmosphere (94% air and 6% CO2) at 37uC. Female
Balb/cAnNHsd mice (Harlan) were immunized with S100A4
fusion protein according to the following protocol. Fifty micro-
grams of S100A4 protein in PBS was used as an emulsion with
Complete Freund’s adjuvant (Sigma) for the initial subcutaneous
immunization and with Incomplete Freund’s adjuvant (Sigma) for
subsequent injections at days 19 and 35. Ten days after the third
injection, sera were obtained and tested. At day-51 a final boost of
25 mg of S100A4 protein in PBS was given intravenously to the
mouse with the highest titrated serum. Fusion was done 4 days
after the last injection. Obtained mAbs were derived from one
fusion of myeloma cells with spleen cells from the selected mouse
at a ratio 1/10, respectively, using PEG-1500 (Roche Diagnostics)
as fusion inducer. Then, cells were plated in 96 microwell dishes in
medium containing HAT (Invitrogen) for hybrids selection.
Hybridoma supernatants were screened for reactivity with
recombinant human S100A4 by ELISA. Clone corresponding to
monoclonal antibody 5C3 was selected for in vitro and in vivo
analyses and subcloned by limiting dilution.
Monoclonal Antibody Production and Purification
Ten liters of serum free supernatant from the hybridoma were
obtained. After filtration, purification was made on protein A
columns (MabSelect SureTM LX; 25 ml, Amersham) using an
A¨KTA purifier FPLC system. Fractions were analyzed by SDS-
PAGE. Eluted antibody was concentrated and diafiltrated in PBS
with AmiconH Ultra-15 centrifugal filter devices with low-binding
UltracelH membranes (30000 NMWL, Millipore). Final condi-
tioned antibodies were quantified at 280 nm.
Cell Culture Conditions
Human Umbilical Vein Endothelial Cells (HUVECs, Lonza)
were cultured on 1% Type B gelatin from bovine skin (Sigma) in
Endothelial cell Basal Medium EBM (Lonza), supplemented with
hEGF, hydrocortisone, brain bovine extract and gentamicine
(EGM, Lonza), and 10% FCS (Invitrogen). HUVECs were used
between passages 6–9 and all experiments were carried out at 80–
85% of confluence, with the same batch of cells. Myeloma
P3X63Ag8.653 (ECACC) cells were cultured in RPMI 1640
(PAA) supplemented with 10% FCS (PAA; Australian origin) plus
2 mM GlutaMAXTM-I (Invitrogen). Colon carcinoma HCT-116
(ECACC), colon adenocarcinoma colo205 (ECACC), breast
adenocarcinoma MDAMB231 (ECACC), melanoma M21 [23]
(used with permission of Dr. D. Cheresh; The Scripps Research
Institute, La Jolla, CA) and pancreatic carcinoma MiaPACA-2
(ECACC) cell lines were cultured in DMEM High-glucose (PAA)
supplemented with 10% FCS (Invitrogen) plus 2 mM L-gluta-
mine. M21-S100A4 overexpressing cell line (Leitat Technological
Center) and MiaPACA-2 underexpressing S100A4 cell line (Leitat
Technological Center) were cultured in DMEM High-glucose
(PAA) supplemented with 10% FCS (Invitrogen) and 1 mg/mL
G418 disulfate salt solution (Sigma) plus 2 mM L-glutamine. All
cells were cultured at 37uC in a humidified 5% CO2-atmosphere,
and were consistently free of mycoplasma as evaluated by EZ-
PCR mycoplasma test kit (Biological Industries).
Development of Stable Cell Lines
M21 melanoma cells, which did not express endogenous
S100A4, were transfected using LipofectamineTM2000 reagent
(Invitrogen) with a control plasmid (mock vector) or a plasmid
encoding S100A4 cloned into the pcDNA3.1 vector and selected
for resistance to G418 (1 mg/mL). Monoclones obtained by
limiting dilution were selected and used for further studies.
Anti-S100A4 mAb Inhibits Tumor Development
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Pancreatic MiaPACA-2 cells, which express high levels of S100A4,
were transfected using FuGENE 6 Transfection Reagent (Roche)
with plasmids encoding for siRNA against S100A4 cloned into
pSilencer 2.1-U6 neo (Ambion) with sense (59-gatccg-cagggacaac-
gaggtggac-ttcaagaga-gtccacctcgttgtccctg-ttttttggaaa-39) and anti-
sense (59-agcttttccaaaaaa-cagggacaacgaggtggac-tctcttgaa-
gtccacctcgttgtccctg-gc-39) sequences corresponding to nucleotides
193 to 213 of S100A4 cDNA (numbering referred to translation
initiation as +1) flanked by BamHI and HindIII restriction sites on
the 59 and 39 ends, respectively, or with a non-related siRNA with
sense (59-gatcc-actaccgttgttataggtg-ttcaagaga-cacctataacaacggtag-
ttttttggaaa-39) and antisense (59-agcttttccaaaaaa-ctaccgttgtta-
taggtg-tctcttgaa-cacctataacaacggtagt-g-39) sequences directed
against a sequence with no corresponding part in the human
genome (actaccgttgttataggtg), used as a control for unspecific
effects of shRNA. Stable expression of both S100A4 siRNA and
control siRNA were established in MiaPACA-2 cells by G418
selection (1 mg/mL) and clonal cell lines were developed by
limiting dilution and used for further studies. The effects of
overexpressing and underexpressing S100A4 were confirmed by
RT-real time PCR and Western blot analysis.
Western Blot Analysis
1) Signaling pathway. Cell lysis and WB analyses were performed
as described previously [24,25] with the following modifica-
tions: before stimulation (see conditions in corresponding
Figures), HUVEC cells were maintained 4 h in EBM alone.
Cells were rinsed twice with PBS and immediately lysed with
ice cold Cell Lysis Buffer (150 mM NaCl, 1% IGEPAL
CA630, 5 mM EDTA, 100 mg/mL PMSF, 1 mM Na3VO4,
1 mM NaF and 50 mM Tris-HCL, pH 7.4). Lysates were
cleared by centrifugation and the protein concentration was
quantified with the Bradford reagent (Bio-Rad). Total extracts
(60 mg) for all analyses were resolved by 7.5% SDS-PAGE
under reduced conditions and transferred to BioTraceTM
PVDF membranes (PALL corporation). Membranes were
blocked for 1 h in TBS plus 0.1% Tween-20 and 5%
skimmed dried milk, incubated overnight with the primary
antibody and then with the secondary antibodies for 1 h in
blocking buffer, with three washes of 10 min each in TBS plus
0.1% Tween-20 after each incubation. Signals were devel-
oped using the ECLTM Western Blotting Detection Reagents
(Amersham) and exposed to HyperfilmTM ECL (Amersham).
In blocking assays, cultures were pre-treated for 2 h with 10–
50–200 nM of the anti-RAGE monoclonal antibody (Chemi-
con) before the addition of S100A4 (3 mM). When using
peptide 3 (30 mM), cells were pre-incubated for 2 h with
S100A4 (3 mM) before incorporated into the cell culture.
2) S100A4 expression. Cells were lysed and total extracts were
resolved by 12% SDS-PAGE. WB analysis was performed as
describe above.
The concentrations/dilutions of the antibodies were as follows:
5C3 mouse monoclonal anti-human S100A4 (Leitat Technolog-
ical Center) at 1 mg/ml; mouse anti-human RAGE (Millipore), at
2 mg/ml; goat polyclonal anti-human KDR (Cell Signaling
Technology), 1:500 dilution; rabbit polyclonal anti-human phos-
pho-KDR (Millipore), 1:250 dilution; rabbit polyclonal anti-
human Tubulin (ICN Biomedicals), 1:5000 dilution; mouse
monoclonal anti-human phospho-p44/42 MAP kinase (Thr202/
Tyr204) (Cell Signaling Technology), 1:2000 dilution; rabbit
polyclonal anti-p44/p42 MAP kinase (Cell Signaling Technology),
1:1000 dilution. Goat anti-mouse (Jackson ImmunoResearch) at
0.04 mg/mL and goat anti-rabbit (Sigma) at a 1:25000 dilution,
were used as secondary antibodies.
Quantitation of the proteins was performed by densitometric
analysis referring the results to the control in the non-stimulated
condition (that represents 100% of expression). All signals
intensities were normalized to a-tubulin.
Real Time-PCR
Total RNA from cells was extracted using Trizol (Life
Technologies) following the manufacturer’s specifications. Quan-
tification of RNA was conducted using a Nanodrop ND-1000
spectrophotometer. cDNA was synthesized in a 20 mL reaction
mixture containing 1 mg of total RNA, 12.5 ng of random
hexamers (Roche), 10 mM dithiothreitol, 20 units of RNasin
(Promega), 0.5 mM each dNTP (AppliChem), 4 mL of buffer (5x),
and 200 units of Moloney murine leukemia virus reverse
transcriptase (RT) (Invitrogen). The reaction was incubated at
37uC for 1 h. An aliquot of this cDNA mixture was used for PCR
amplification by real time. The StepOnePlusTM Real-Time
methodology from PCR Systems (Applied Biosystems) was used
to perform these experiments. Taqman probes (Applied Biosys-
tems, Barcelona) were used to determine mRNA levels of S100A4
(HS00243202_M1), AGER (Hs00542584_g1), and Adenine
phosphoribosyltransferase (APRT) (HS00975725_M1), where
APRT was used as an endogenous control. The final volume of
the reaction was 20 mL, containing 1x TaqMan Universal PCR
Mastermix (Applied Biosystems), 1x TaqMan probe (Applied
Biosystems), 3 mL of cDNA and MQH2O. PCR cycling
conditions were 10 min denaturation at 95uC, followed by 40
cycles of 15 s at 95uC and 1 min at 60uC. The mRNA amount of
the target gene was calculated using the DDCT method, where CT
is the threshold cycle that corresponds to the cycle where the
amount of amplified mRNA reaches the threshold of fluorescence.
NF-kB Electrophoretic Mobility Shift Assay (EMSA)
To determine NF-kB nuclear translocation, HUVEC cells were
maintained for 2 h in EBM and then stimulated with S100A4
(3 mM) in EBM for 20 minutes at 37uC. In blocking assays,
cultures were pre-treated for 2 h with 200 nM of the anti-RAGE
monoclonal antibody (Chemicon) before the addition of S100A4.
Alternatively, 30 mM of peptide 3 was pre-incubated for 2 h with
S100A4 before its addition to the cell culture. Nuclear extracts
were prepared and used for EMSA as previously described
[26,27]. For binding reactions, 2 mg of nuclear extract were used
in 20 mL in 15 mM Tris-HCl, pH 8, containing 15 mM NaCl,
0.5 mM EDTA, 60 mM KCl, 1 mM PMSF, and 0.006% b-
mercaptoethanol. The binding reaction was started by the
addition of the 22-bp ds oligonucleotide 59-AGTTGAGGG-
GACTTTCCCAGGC –39 (20,000 cpm) containing the NF-kB
consensus sequence (underlined), end-labelled with [c232P]-ATP
(3000Ci/mmol) and T4 polynucleotide kinase [24]. The binding
reaction was allowed to proceed for 1 h at room temperature. For
competition experiments, excess of unlabeled NF-kB oligonucle-
otide (2.5X or 5X) was added to the binding reaction as specific
competitor 15 minutes before the addition of the labelled probe.
For supershift assays, 2 mL of specific antibodies against NF-kB
protein subunits p65/p50 (Santa Cruz Biotechnology) were
incubated with nuclear extracts overnight at 4uC before the
addition of the labelled probe. All reaction mixtures were
subjected to PAGE on 6% gel in 0.5X TBE and run for 2 h at
200 V. Gels were dried and exposed for 4 h to Europium screens.
Quantification was performed using a Storm 860 phosphorImager
(GE Healthcare, Life Sicences).
Anti-S100A4 mAb Inhibits Tumor Development
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Interaction between S100A4 and RAGE by Surface
Plasmon Resonance (SPR)
SPR measurements were performed on a T100 Biacore system
(GE Healthcare Europe GmbH, Germany) as described previously
[28] with some modifications. About 1,000RU of human
recombinant RAGE-Fc Chimera (R&D Systems) were immobi-
lized as ligand on CM5 sensor chips (Amersham) using standard
amine-coupling protocol. Various concentrations of human
recombinant S100A4 ranging from 0.625 to 5 mM were passed
over the surface of the sensor chip at a flow-rate of 15 mL/min
(60 sec. contact time). After each cycle, the surface was regener-
ated using 50 mM NaOH. For the competition assay, 2 mM of
S100A4 was incubated with various concentrations of 5C3 anti-
S100A4 mAb ranging from 60 nM to 500 nM, before applying to
the chip. The data were analyzed with the Biacore Evaluation
Software version 1.1.
Migration Assay
Transwell migration assays were performed as described
previously [29], with the following modifications: The Transwell
HTS FluoroBlokTM Multiwell Insert System with 8 mm-pores
(Becton Dickinson) was used to test the activities. The upper and
lower surfaces of the membranes were coated with 15 mg/mL of
Type I Collagen (Upstate) to improve the cell adhesion. Cells
(56 104 in EBM without serum or other supplements) were plated
onto the upper side of the transwell and were incubated for 4 h at
37uC. Different concentrations of S100A4 (0.3, 1 or 3 mM), alone
or in combination with VEGF (1, 3 or 10 ng/mL), in EBM
without supplements were simultaneously added, just after cell
seeding, to the lower compartment to test their chemotactic
capacity. To test the inhibitory effect of the anti-RAGE mAb
(Chemicon), 0.02, 2, or 200 nM of the antibody were added to the
upper chamber of the insert 2 h before the stimulus with S100A4.
To check the effect of the 3 peptides homologous to three regions
of RAGE, 30 mM of each one were incubated with 3 mM of
S100A4 two hours before adding both S100A4 and VEGF to the
lower chamber to initiate migration. To check the inhibitory effect
of the 5C3 mAb, 0.25, 0.5, 1, 2 or 4 mM of the antibody were
incubated 2 h with S100A4 and VEGF or VEGF alone, before
adding both to the lower chamber to initiate migration. All
migratory effects were analyzed after 24 h, and migrated cells
were stained and counted under a light microscope at a
magnification of X10. All experiments were normalized to the
positive control of cells incubated with EBM complete medium
that represents 100% migration. The control is the maximum of
the possible migration (migration control).
MMP Activity Assay
Gelatin zymography analysis was performed as described
previously [30] with the following modifications: Before stimula-
tion, cells were maintained 4 h in EBM without serum or other
supplements. Then, S100A4 (0.3, 1 or 3 mM) in EBM was added
to the culture to analyze its capacity to increase the secretion of
active forms of MMPs. To test the inhibitory effect of 5C3 mAb,
1–2 mM of the antibody were incubated 1 h with S100A4 (1 mM),
before adding both to the culture. After 24 h at 37uC,
supernatants were resolved in a non-reducing 8% SDS-PAGE
gel copolymerized with Type A gelatine from porcine skin (Sigma)
at a final concentration of 1 mg/mL. After running, MMPs
present in the gel were activated for 48 h, gels were stained and
bands were quantified using the NIH ImageJ imaging software.
Cytotoxic Effect of Gemcitabine and 5C3 mAb
The cytotoxic effects of Gemcitabine and the 5C3 mAb were
measured by hexosaminidase activity and by bromodeoxyuridine
(BrdU) incorporation assay. Briefly, MiaPACA-2 cells were plated
onto 96-well cell culture dishes (56 103 cells/well) in 50 mL of
culture medium. Twenty-for hours later, 50 mL of medium with
several concentrations of Gemcitabine alone or in combination
with 5C3 (40 nM, 100 nM) was added to each well and cells were
cultured for 72 h. BrdU incorporation was determined using the
Cell Proliferation Biotrak ELISA SystemTM kit (Amersham
Biosciences) according to the manufacturer’s instructions. For
hexosaminidase activity analysis, cells were washed once with PBS,
after discarding the culture media. Sixty microliters of substrate
solution (7.5 mM 4-nitrophenyl-N-acetyl-beta-D-glucosaminide,
0.1 M sodium citrate, 0.25% Triton X-100, pH 5.0) was added
to each well and dishes were incubated at 37uC for 2 h. Color was
developed by adding 90 mL of developer solution (50 mM glycine,
5 mM EDTA, pH 10.4), and the absorbance at 450 nm was
measured by using a Multiskan Ascent spectrophotometer
(Thermo Corporation). Data analysis was performed by normal-
izing the results with the negative control (untreated cells) that
were considered as 100% of viability. Curves were adjusted using a
sigmoid dose-response (variable slope) equation, and EC50 values
were obtained from the equation:
Y~ Bottomz (Top-Bottom)
=(1z 10^ ((LogEC50-X) �HillSlope)),
where X is the logarithm of concentration and Y is the response. Y
starts at Bottom and goes to Top with a sigmoid shape.
To evaluate the level of interaction (synergistic, additive or
antagonist effect) between Gemcitabine and 5C3, a variation of
the method proposed by Chou-Talalay was used [31]. Briefly, the
effect of the gemcitabine plus 5C3 was quantified by the
combination index (CI):
CI~ ((D)1=(Dm)1)z ((D)2=(Dm)2)
where (Dm)1 and (Dm)2= doses of the chemicals that when applied
singlyalsohavethesameeffectand (D)1and(D)2 = dosesofchemicals
1 and 2 that in combination produce some specified effect.
Determining values (synergism, addition, antagonism) using the
CI index as shown in Table 1:
Tumor Growth Studies in Nude Mice
Mice for tumor models (athymic (Hsd:Athymic Nude-
Foxn1nu; 6–7 weeks old)) were from Harlan Laboratories
Models, S.L. (Barcelona, Spain). They were maintained within
Table 1. Combination index (CI) value description.
Value
range Description
Value
range Description
,0.1 Very strong synergism 0.90–1.10 Nearly additive
0.1–0.3 Strong synergism 1.20–1.45 Slight antagonism
0.3–0.7 Synergism 1.45–3.3 Antagonism
0.7–0.85 Moderate synergism 3.3–10 Strong antagonism
0.85–0.9 Slight synergism .10 Very strong antagonism
doi:10.1371/journal.pone.0072480.t001
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the Barcelona Science Park (PCB) animal care barrier facilities.
Pancreatic MiaPACA-2 (ECACC) and melanoma M21-S100A4
(used with permission of Dr. D. Cheresh; The Scripps Research
Institute, La Jolla, CA) cell lines were subcutaneously injected
into the right flank of nude mice (56 106 or 16 106 cells for
MiaPACA-2 or M21, respectively). Tumor growth was calculated
using the formula: Volume~ (Dxd2)=2, where D is the longest
axis of the tumor and d is the shortest. To study the
antitumorigenic capability of the 5C3 mAb, mice were treated
either with vehicle (PBS) or with the antibody by i.p. route three
times per week at 25 mg/Kg/5 mL of sterile PBS, starting the
treatment at a mean tumor volume of approximately 100 mm3
for MiaPACA-2 and 115 mm3 for M21-S100A4 cell lines. We
calculated the treatment-to-control ratio (of sample means) at the
end of experiment and it corresponds to the observed RTV
(Relative Tumour Volume) at a given time for the treatment and
control groups, respectively. At the end of the experiment animals
were sacrificed, tumors were surgically removed and weighed.
Tumors were embedded in O.C.T. compound (Tissue-TekH,
Sakura) and paraffin for subsequent immunostaining analyses.
Blood from all animals was collected by intracardiac puncture for
posterior analyses.
Immunohistochemical CD31 Staining
At the end of the in vivo experiments, subcutaneous tumors
from MiaPACA-2 and M21 cells were OCT (Tissue-TekH,
Sakura) embedded and frozen. One cryosection (5 mm) corre-
sponding to the central part of each tumor was analyzed. Sections
were fixed in acetone/chloroform (1:1) at -20uC for 5 min, dried
overnight at room temperature, washed with PBS and treated for
10 min at 4uC in a dark chamber with H2O2 (0.03%) in PBS.
Then, sections were washed with PBS and blocked for 20 min at
4uC using PBS-BSA (2%) plus rabbit serum (5%) (Vector) and
with Avidin-biotin blocking solution (Dako) for 10 min each one
at 4uC. Samples were incubated for 1 h at room temperature
with primary antibody; a monoclonal rat anti-mouse antibody
directed against CD31 (dil 1:200, BD PharMingen) diluted in
blocking buffer. Afterwards, sections were incubated with a
polyclonal biotinylated anti-rat antibody as secondary antibody
(dil 1:500, Vector) for 30 min at room temperature and then the
ABC reagent (Pierce) was added for 30 min at room temperature.
Finally, sections were incubated with NovaRed (Vector) for
20 min at 4uC, stained with Haematoxylin Harris (Sigma) for 10
seconds and mounted using DPX non-aqueous mounting
medium (Sigma). Angiogenesis quantification was measured
using two criteria [3,32]:
M :V:D :(v:p:=mm2)
~ 106|
Sum of vessels of each tumor (imageAz imageBz :::z imageN)
Area of one tumor in mm2(areaAz areaBz :::z areaN)
A:A:(fractional area of vessels)
~ Area of vessels of each tumor (imageAz imageBz :::z imageN)Area of one tumor in mm2(areaAz areaBz :::z areaN)
Given that the surfaces of the images taken are expressed in
mm2 and the unit in the formula is expressed in mm2, a factor of
106 was applied. We used individual microscopic field areas to
determine the vessel density. However, in order to have a more
representative value of total vasculature more than 10 pictures
per slice, depending on the size of tumors, were taken and
analyzed using the NIH ImageJ imaging software.
Determination of Secreted S100A4 Protein by Sandwich
ELISA Assay
To measure the presence of S100A4 in plasma samples from
animals with or without tumor, a sandwich ELISA assay was
performed as described previously [33] with the following
modifications: Blood samples were obtained at the end of the
experiments (subcutaneous tumors from HCT116, MDAMB231,
MiaPACA-2 and Colo205 cell lines) by intracardiac puncture,
after euthanasia. Samples for monitoring over time from animals
bearing MiaPACA-2 tumors (expressing and non-expressing
S100A4 protein) were collected weekly by facial puncture. All
materials used were EDTA-coated. Immediately after withdraw-
al, blood samples were centrifuged at 5,000 rpm for 10 minutes at
RT and stored at 220uC until analysis. S100A4 plasma levels
were measured by a dual antibody sandwich immunoassay. 96
microtiter dishes (Maxisorb, NUNC) were coated with 10 mg/mL
of 5C3 mAb diluted in PBS 24 h at 4uC. After removing the
coating, dishes were washed twice with PBS and incubated 1 h at
37uC in blocking buffer (PBS containing 1% of skimmed milk).
Plasma samples diluted 1:4 in dilution buffer (PBS-4% BSA) were
added to the wells and incubated 2 h at 37uC. Dishes were
washed eight times with washing buffer (PBS-0.1% Tween-20)
and Rabbit polyclonal anti-S100A4 secondary antibody (Dako) at
4 mg/mL was added to the wells which were incubated for 1 h at
37uC. Dishes were washed eight times with washing buffer, goat
anti-rabbit-IgG-peroxidase conjugated (Sigma) at 1:12,500 dilu-
tion was added to each well and incubated 1 h at 37uC. After
washing eight times with washing buffer, the ELISA was
developed by the addition of Tetramethylbenzidine substrate
(Sigma) followed by incubation for 30 min at RT before stopping
the reaction with 1 M of HCl. Absorbance was measured at
450 nm using a Multiskan Ascent spectrophotometer (Thermo
Corporation). A standard curve was constructed by plotting
absorbance values versus human S100A4 concentrations of
recombinant protein (serial 1:3 dilutions in blocking buffer
starting at 8.4 mg/mL), and concentrations of unknown samples
were determined using this standard curve. Correlation coeffi-
cient between plasma levels and tumor volume in subcutaneous
MiaPACA-2 tumor model was obtained by linear regression. To
measure the presence of secreted S100A4 in cell culture media,
M21 (mock vector and S100A4 overexpressed), MiaPACA-2
(mock vector and S100A4 silenced) and HUVECs cells, were
cultured in a 6-well plate with complete media until reaching
100% of confluence. Then, media were replaced for 2 mL of
fresh serum free media after washing the cells twice with PBS.
Supernatants were collected after 48 h and cleared by centrifu-
gation. Presence of S100A4 protein was analyzed as we
previously described for plasma samples.
Statistical Analysis
In all studies, values are expressed as mean 6 standard error of
the mean (SEM) as indicated. Statistical analyses were performed
by the two-tailed nonparametric Mann Whitney U test, using the
GraphPad Prism software, version 5.04 for Windows. Differences
were considered statistically significant at p,0.05.
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Results
S100A4 and VEGF Exert a Synergistic Effect on HUVECs
Migration, Increasing KDR Protein Expression and the
Production of Active forms of MMP-9
To further extend previous studies about the cellular mecha-
nism of action of S100A4 in the angiogenic process [8,34] we
focused our work on the extracellular induced migratory capacity
of this protein in HUVEC. S100A4 was tested in the dose range of
0.3–3 mM, exhibiting a small but significant migration activity at
3 mM (two-fold increased as compared to the negative control
EBM). Incubation of HUVEC with 1, 10 or 100 ng/mL of VEGF
alone increased migration in a dose dependent manner, by 3, 5
and 10-fold, respectively, as compared to EBM. To determine the
effect of VEGF alone the migration observed by VEGF was
divided by the migration obtained with the basal medium.
However, when VEGF (1 or 10 ng/mL) was combined with
S100A4 (0.3 or 3 mM), the effect on migration was synergistic
(Fig. 1A). S100A4 and VEGF shows less migration than the
control because those experimental points lack 10% FCS plus
hydrocortisone, brain bovine extract and hEGF, and contains only
basal medium. Therefore, this condition determines only the effect
due to S100A4 and VEGF.
In particular, when 3 mM of recombinant S100A4 was added
together with 1 ng/mL VEGF, migration was increased by 2.5-
fold compared to the effect of VEGF alone. To obtain the 2.5 fold
increase it is needed to subtract the basal migration (7% of the
control) obtained in the absence of any stimulus. The combination
index (Chou-Talalay method) that evaluates the level of interac-
tion between the two proteins was 0.32, demonstrating a
synergistic effect between S100A4 and VEGF. We also tested if
bFGF, could exert a similar synergy together with S100A4.
However, this combination was not synergic on the stimulation of
HUVEC migration (data not shown).
To gain insight into one possible molecular mechanism to
explain the observed synergic activity, we quantified the expression
of KDR by Western Blot based on the effect observed in similar
in vitro assays between VEGF and bFGF [35,36,37]. A dose-
dependent effect in KDR expression was observed 24 h after
S100A4 stimulation, resulting in a 6, 12 or 20-fold increase at 0.3,
3 or 30 mM S100A4, respectively, compared to the control. VEGF
increased KDR expression about 12-fold, although maximum
response was already observed with 1 ng/mL (Fig. 1B). Interest-
ingly, the combination of VEGF (10 ng/mL) with S100A4 (3 mM)
increased KDR protein expression by 30-fold (Fig. 1C), whereas
VEGF or S100A4 alone increased only by 12-fold each, resulting
in a clear synergistic effect for the combined activity of the two
proteins that could explain the observed increase on migration.
The concentration of 10 ng/mL VEGF was used since there was
still a slight increase when compared with 1 ng/mL to be sure that
we were at a steady level of VEGF to detect the increment in
combination with S100A4.
In addition to KDR expression, we also checked the levels of
KDR phosphorylation 24 h after stimulation with S100A4 (3 mM),
VEGF (10 ng/mL) or by the combination of the two proteins. We
observed that only VEGF increased KDR phosphorylation about
2-fold compared to the control at this time point (Fig. 1C). To
correlate the increase in KDR expression with the activity
mediated by the receptor induced by the combination of
S100A4 and VEGF, a more detailed time course including 4 h
and 8 h was also carried out determining both, the expression and
he phosphorylation of KDR. It is observed that at 8 h of
incubation with S100A4 plus VEGF there was a 2-fold increase in
the phosphorylation of KDR compared with that produced by
VEGF alone (Fig. 1D).
To further explore the ability of extracellular S100A4 to
increase the expression and the activity of MMPs that led the cell
movement and invasion [9,38,39] we investigated the production
and secretion of activated forms of MMP-2 and MMP-9 to the
conditioned medium of HUVEC after S100A4 stimulation. While
no differences were observed on MMP-2 activation, a more
activated form of MMP-9 was observed in cells treated with
S100A4 as shown by a blanched area (arrow head in Fig. 1E), that
was not detected in the medium from cells maintained in the cell
culture medium alone.
Taken together, these results on EC migration, present a novel
mechanism of synergistic action between VEGF and S100A4 in
the angiogenic process, by overexpressing KDR and generating
activated forms of MMP-9.
5C3 Monoclonal Antibody Blocks the Cellular Activity of
S100A4 in Endothelial Cells
We next investigated the in vitro neutralizing activity of a novel
specific mAb against murine and human S100A4, developed in
our laboratory, named 5C3. Due to the small effect induced by
S100A4 alone on migration, we used the combination of VEGF
and S100A4 to test for the efficacy of the antibody. As the synergic
effect between S100A4 and VEGF was obtained at different
combinations, we decided to test intermediate concentrations, that
is 3 ng/mL of VEGF and 1 mM S100A4. Treatment with 5C3
abolished in a dose-dependent manner the synergistic effect of the
combination of VEGF and S100A4 on EC migration. This
neutralizing activity of 5C3 was statistically significant (Fig. 1F). It
is noteworthy that the antibody did not affect migration induced
by the vascular endothelial growth factor alone, demonstrating
that the blocking effect was exclusive of the activity of S100A4
protein. By contrast, another anti-S100A4 mAb, 5H4 (same
isotype as the 5C3 mAb), did not show any neutralizing effect
(Fig. 1F).
In addition, when we assessed the 5C3 impact on the potential
of S100A4 to increase the production of active forms of MMP-9,
we observed a total inhibition of these forms (Fig. 1G).
S100A4 Functions via RAGE in Endothelial Cells
Previous studies revealed that several S100 family members,
including S100A4, function extracellularly through their binding
to RAGE [13]. Accordingly, we presumed that RAGE could be
the receptor responsible for the S100A4-induced effects in EC by a
mechanism of action not yet described. To test this hypothesis, we
set up different experiments.
As a first choice we employed an anti-RAGE mAb to inhibit the
binding of S100A4 to this receptor. Using increasing concentra-
tions of this antibody to abolish the synergistic migration effect of
the combination of VEGF plus S100A4 on HUVEC, a dose-
dependent inhibition was observed (Fig. 2A). The specificity of this
action was also confirmed since the antibody did not affect cell
migration induced by VEGF alone.
To further confirm this interaction, we designed and synthe-
sized three peptides homologous to three different regions of the
extracellular domains of the receptor to block the putative
activation of RAGE by S100A4. One peptide (P1) corresponded
to the extracellular domain Ig-C1, and two peptides (P2 & P3)
corresponded to the extracellular domain Ig-V1. Preincubation of
the peptides with S100A4 showed a maximum and statistically
significant blocking effect by P3 on HUVEC migration (Fig. 2, B
and C), supporting previous studies that sustain Ig-V1 as the
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Figure 1. S100A4 acts synergistically with VEGF on HUVEC migration, by increasing KDR expression and the production of active
MMP-9. A) Dose-response of VEGF and S100A4. Cells were treated with EBM, S100A4, VEGF, or the combination of S100A4 plus VEGF for 24 h and
migration was analyzed. B) Western-blot analysis of KDR expression after adding either S100A4 (0.3–30 mM) or VEGF (1–100 ng/mL) for 24 h. C) Levels
of KDR expression and activation (phosphorylation) induced by VEGF (10 ng/mL), S100A4 (3 mM) or by the combination of the two proteins for 24 h
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interacting region between S100 proteins and RAGE activation
[40].
A third approach included the study of the signaling pathway
downstream RAGE [41,42]. Incubation of HUVEC with S100A4
induced ERK1/2 phosphorylation in a time-dependent manner,
with a noticeable effect after 15 min (Fig. 3A). VEGF also induced
ERK1/2 phosphorylation, but the combination of VEGF plus
S100A4 increased the level of phosphorylation compared to the
of stimulation. All KDR signal intensities were normalized to a-tubulin. D) Time course (4 h and 8 h) of KDR expression and KDR phosphorylation
upon incubation with S100A4 (3 mM) or VEGF (10 ng/mL) or the combination of the two proteins. E) Proteolytic activity of MMPs in HUVEC
conditioned media. Cells were treated with S100A4 in EBM alone for 24 h. Active forms of MMP-9 induced by S100A4 are indicated by arrowheads. F)
HUVEC were treated with VEGF (3 ng/mL), VEGF plus S100A4 (1 mM) or the combination of these proteins with the antibody 5C3 (0.25–4 mM) for
24 h. 5H4 was used as non-blocking antibody. G) 5C3 (1–2 mM) neutralized the production of active forms of MMP-9 induced by S100A4 (arrowhead).
Each data point was normalized to the positive control of cells incubated with complete medium (left bar) that represents 100% migration. The
control is the maximum of the possible migration (migration control). This migration is obtained by incubating HUVEC with basal medium containing
10% FCS plus hydrocortisone, brain bovine extract and hEGF. All the experimental points are referred to this control. Bars show the mean 6 SEM. ns
p.0.05, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0072480.g001
Figure 2. S100A4 acts via RAGE on EC migration. A) Dose-response activity of anti-RAGE (0.02–200 nM) on HUVEC migration. After starvation,
cells were incubated with an anti-RAGE mAb for 2 h and then treated with VEGF (10 ng/mL) or VEGF plus S100A4 (3 mM), respectively, for 24 h. B)
Design of homologous peptides to the extracellular domains of RAGE. C) Before migration, peptides were incubated with S100A4 for 2 h at 37uC,
then HUVEC were treated with VEGF (10 ng/mL) or VEGF plus S100A4 (3 mM) with 30 mM of each peptide respectively for 24 h. Each data point was
normalized to the positive control (left bar) that represents 100% migration. Bars show the mean 6 SEM. ns p.0.05, *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0072480.g002
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Figure 3. Extracellular S100A4 acts via RAGE in HUVECs, stimulating the ERK1/2, NF-kB signaling pathway and KDR expression.
Cells were treated with the indicated proteins in EBM alone. Signal intensities were normalized to a-tubulin. A) Levels of ERK1/2 phosphorylation
induced by 3 mM S100A4 for the indicated periods of time. B) Levels of ERK1/2 phosphorylation induced by S100A4 (3 mM), VEGF (10 ng/mL) and
S100A4 plus VEGF for 15 min. Levels of ERK1/2-dependent S100A4 and VEGF phosphorylation by using the anti-RAGE mAb. C) Levels of ERK1/2
phosphorylation induced by S100A4 (3 mM) for 15 min either in the absence or in the presence of P3. D) Dose-dependent effect of anti-RAGE (10–
200 nM) on S100A4-induced KDR expression. E) NF-kB binding in control cells (c) and cells treated (st) with S100A4 (3 mM) and competitions with
2.5X and 5X-fold excess of unlabelled NF-kB ds oligonucleotide. F) Supershift analysis: nuclear extracts were incubated overnight at 4uC in the
presence of anti-p50 (arrow) and anti-p65 (arrowhead) antibodies before the addition of the consensus NF-kB probe. G) Gel-shift using the consensus
NF-kB probe and nuclear extracts from control HUVEC (c), cells treated (st) with S100A4 (3 mM) or with the anti-RAGE antibody (200 nM), 2 h before
S100A4 stimulation.
doi:10.1371/journal.pone.0072480.g003
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levels observed with either S100A4 or VEGF alone. ERK
activation was inhibited by the addition of anti-RAGE antibody
showing a dose-dependent effect or by pre-incubating S100A4
with P3 (Fig. 3B and C). The combination of VEGF and RAGE
antibody did not show differences compared with VEGF alone
without antibody (Fig. 3B).
In addition, we investigated whether suppression of RAGE
signaling could inhibit S100A4-induced KDR expression. Using
the anti-RAGE mAb a dose-dependent inhibition of the KDR
protein was observed, which was completely cancelled at a
concentration of 50 nM of anti-RAGE (Fig. 3D).
Incubation with S100A4 caused an increase in NF-kB binding
as analyzed in HUVEC nuclear extracts. Four NF-kB bands were
observed in the gel-shift assays upon S100A4 stimulation, whereas
only two bands were obtained with non-stimulated cells. Binding
was specific as shown by competition experiments using an excess
of unlabeled ds oligonucleotide containing the NF-kB consensus
binding-site (Fig. 3E). Super-shift analyses using specific antibodies
for the NF-kB subunits identified the presence of p50 and p65 in
the bound complexes (Fig. 3F). Activation of NF-kB binding by
S100A4 was inhibited by RAGE antibody (Fig. 3G), reverting the
pattern of binding to that observed with control extracts.
Finally, we sought to check this interaction by surface plasmon
resonance. The analysis of the sensorgram obtained in the
BiaCORE after passing 0.625, 1.25, 2.5 and 5 mM of S100A4
over RAGE showed a clear dose-dependent response with the
characteristic association and dissociation slopes of a true
interaction between both molecules (Fig. 4A). As expected, dose-
response inhibition of S100A4-RAGE interaction by the 5C3 mAb
(60–125–250–500 nM) was observed with 2 mM of S100A4,
confirming the neutralizing effect of the antibody against
S100A4 not only at the cellular but also at the molecular level
(Fig. 4B).
Overexpression of S100A4 Promotes an Increased in vivo
Angiogenesis and Tumor Growth
There are few data on the in vivo implication of extracellular
S100A4 protein in tumor growth. Some authors revealed its
potential role increasing tumor angiogenesis [8,17], but so far no
evidences of directed therapies against its extracellular function
demonstrate its proof of principle.
According to the literature, the active extracellular form of the
protein is forming oligomers whereas the intracellular is not. This
conformational structure is essential for its extracellular function.
To address the question of whether S100A4 could serve as a
therapeutic target in vivo, we evaluated the effect of S100A4
overexpression in a non-expressing human melanoma cell line
(M21). After stable transfection, we selected by WB the clone with
the highest expression and its function was evaluated in vitro and
in vivo compared with cells transfected with the mock vector. The
proliferation assay showed no differences between both cell types
(data not shown), but after subcutaneous implantation in athymic
mice, we observed a statistically significant increase of tumor
volume when comparing S100A4-overexpressing cells to their
control counterpart (Fig. 5A). Although the presence of intracel-
lular S100A4 does not affect tumor cell proliferation we
demonstrated the secretion of S100A4 in cell lines expressing this
protein (Fig. S1C). This secretion affects in vivo the neovascular
formation and therefore increases tumor growth. Keeping in mind
the angiogenic role displayed by S100A4, we analyzed the
formation of new microvascular vessels into the tumor in order
to give a possible explanation of the dramatic observed tumor
increase. Quantification of the microvessel density and the fraction
area of the vessels revealed a remarkably gain of angiogenesis in
tumors from animals bearing S100A4 positive cells (Fig. 5C).
To support that the observed effect was depending on the stable
expression of the protein, we analyzed the presence of human
S100A4 (either at mRNA or protein levels) on transfected cells
(Fig. S1A and B).
To determine the possible activity of S100A4 via RAGE in
these cells, we analyzed also the presence of the receptor (mRNA
and protein) confirming, that effectively, all cells express RAGE
without variations due to the transfection (Fig. S1A and B).
5C3 Decreased Tumor Growth in M21-S100A4
Overexpressing Cell Line
To further determine the role of extracellular S100A4 in
increasing tumor growth, we next sought to quantify whether anti-
S100A4 therapy was associated with a decreased tumor develop-
ment in the M21 model. We started the treatments when solid
tumors were well established (mean tumor volume 115 mm3), and
continued it for 18 days. The comparison between the activity of
the 5C3 antibody and the control group revealed a potent anti-
tumoral effect with a decrease of 45.1% in the T/C ratio of tumor
volume (Fig. 5B). Tumor weights showed differences statistically
significant, with a T/C ratio of 48.1%.
In addition, we investigated the possible role of 5C3 in blocking
tumor angiogenesis thus affecting tumor growth. Histological
analyses of murine CD31 staining were performed for all tumor
samples at the end of the experiments. Quantification of
microvessel density and the fraction area of the vessels revealed
an important decrease in the formed vasculature, with an
inhibition about the 60% in vascular density with respect to
non-treated animals (Fig. 5C).
Knockdown of S100A4 Induced in vivo Tumor Growth
Suppression
The role of S100A4 protein in in vivo tumor development was
explored by knocking-down its expression in the human pancreatic
adenocarcinoma MiaPACA-2 cell line using interfering RNA
technology. Then, we determined its effect on tumor progression
as in previous studies with osteosarcoma [43] or esophageal
squamous carcinoma cells [44].
After stable transfection, we selected by WB the clone with the
lowest S100A4 expression and its function was evaluated in vitro
and in vivo by comparison with cells transfected with the mock
vector. The proliferation assay showed no differences between
both cell types (data not shown), but after subcutaneous
implantation we observed a dramatically reduced rate of tumor
growth for non-expressing S100A4 MiaPACA-2 cells; only 5 out of
the 15 animals developed tiny tumors compared with the S100A4
expressing counterpart where all 15 animals developed big tumors
(Fig. 6A).
We next investigated the possible correlation between the
presence of S100A4 protein in plasma and tumor burden and we
found an increase in animals bearing positive S100A4 tumors,
following the same pattern as the growth of the corresponding
tumors, whereas no S100A4 was detected in animals bearing
shRNA-S100A4 cells (Fig. 6B). A statistically significant correla-
tion was established between tumor volume and the levels of
plasmatic S100A4 (Fig. 6C), and the analysis by RT-PCR and WB
demonstrated the presence of mRNA and S100A4 protein,
respectively, only in cells transfected with the mock vector
compared with the transfected with shRNA-S100A4 (Fig. S1A
and B).
Anti-S100A4 mAb Inhibits Tumor Development
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e72480
To further explore the potential usefulness of the S100A4
protein as a plasmatic biomarker for diagnosis, we quantified the
levels of S100A4 in plasma samples obtained from four different
xenograft tumor models (MiaPACA-2, MDA-MB-231 from breast
adenocarcinoma, and Colo205 and HCT116 from colon carci-
noma cell lines). Experimental data demonstrated the consistent
difference between the basal expression of S100A4 protein in
animals without tumors and its expression in animals with tumors
(Fig. S2).
Decreased Tumor Growth in Response to Extracellular
S100A4 Blockade with 5C3 in MiaPACA-2 Cell Line
To address the question of whether 5C3 mAb could serve as a
therapeutic agent in vivo to neutralize the effect of S100A4 secreted
by MiaPACA-2 cell line, we treated athymic mice bearing
subcutaneous tumors.
Treatment was initiated 17 days after cell implantation for
MiaPACA-2 (mean tumor volume of each group higher than 100
mm3) (day 0), and tumors were collected at day 30 after treatment.
5C3 was given by i.p. route (25 mg/kg/5 mL), administered on a
three times a week schedule. At the end of the experiment the
control group (vehicle) exhibited maximum tumor growth with
mean relative tumor volume (RTV) of 592% respect to the initial
volume (before treatment). Tumor volume changes in 5C3-
injected mice showed a maximum mean RTV of 274% respect
to the initial volume. We observed that treatment with 5C3 also
induced a statistically significant decrease in tumor weight
compared with the control group (Fig. 7A). In addition, these
differences were reflected on the calculated T/C ratios of tumor
volume and tumor weight, 46%, and 38%, respectively.
We next investigated whether the 5C3 would actually affect
tumor angiogenesis in vivo and consequently in part the tumor
development. Quantification of MiaPACA-2 tumors from animals
treated with the 5C3 mAb showed a statistically significant
reduction of approximately 40% in microvessel density and 30%
Figure 4. S100A4 interacts with RAGE. A) Molecular interaction between S100A4 and RAGE by SPR. Overlayed sensorgrams of interaction
between immobilized RAGE and S100A4 at four different concentrations. Numbers 1 and 2 indicate the start and the end of S100A4 injection,
respectively. B) Dose-response inhibition of S100A4-RAGE interaction by 5C3 mAb. Antibody was used at 60–500 nM for 2 mM S100A4.
doi:10.1371/journal.pone.0072480.g004
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of the section area occupied by vessels compared with animals
from the control group (Fig. 7B).
To gain insight into a possible combinational effect of 5C3 with
conventional chemotherapy (Gemcitabine), a standard first-line
treatment for advanced pancreatic cancer, we investigated the
cytotoxic effect caused by the two agents in MiaPACA-2 cell line.
It is noteworthy that the effect in cell viability induced by
treatments with Gemcitabine alone and in combination with two
concentrations of 5C3 showed a decrease in EC50 (Fig. S3A). In
addition, the CI index that evaluate the level of interaction
between two drugs, demonstrated a synergistic effect between the
two compounds. In these experiments, proliferation was also
determined. Figure S3B showed a decrease in EC50 reflecting that
5C3 had an antiproliferative effect in neutralizing the extracellular
role played by S100A4 protein.
Discussion
There is a great need for understanding the mechanisms
behind the angiogenic process and the metastatic spread of
Figure 5. Tumorigenic study with stable S100A4 transfected cells in M21 xenograft model and effect of 5C3 on tumor growth. A)
Comparison of tumor growth from M21 cells transfected either with human S100A4 or with mock vector. Groups had 15 animals. Bars of tumor
weight show the mean 6 SEM. *p,0.05. B) Antitumor activity of 5C3 in M21-S100A4 tumors. PBS (negative control) or 5C3 (25 mg/kg) was given i.p.
three times a week (1010100) to 5 animals per group. At the end of the experiment, mice were sacrificed and tumors were weighted. Graphs of RTV
show the activity of 5C3 compared with the control group. Bars of tumor weight show the mean 6 SEM. *p,0.05 by. C) Immunohistology of tumor
microvasculature analyzing CD31 staining. Box and whiskers graphs show the vascular density in a defined tumor area (MVD) expressed as the mean
of vascular profiles (v.p.) per mm2, and the quantification of vessel area in the tumor (Aa). Quantifications were made from more than 10 pictures per
slice at a magnification of X120 (2.4 mm2). Images were analyzed using the NIH ImageJ software. Graphs show the mean 6 SEM. ns p.0.05, **p,0.01.
doi:10.1371/journal.pone.0072480.g005
Figure 6. Tumorigenic study on MiaPACA-2 xenograft model silencing S100A4. A) Tumor growth of MiaPACA-2 transfected either with the
pSilencer vector encoding for a shRNA against human S100A4 or for a non-related shRNA were compared. Groups had 15 animals. Graphs represent
only animals that developed tumors. Bars of tumor weight show the mean 6 SEM. ***p,0.001. B) S100A4 plasma levels in MiaPACA-2 transfected
with shRNA-S100A4 or with a non-related shRNA were measured once a week. C) Correlation between plasma levels of S100A4 protein and tumor
burden. Graphs of plasma levels show the mean 6 SEM. **p,0.01. r2 represents the coefficient of determination.
doi:10.1371/journal.pone.0072480.g006
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tumors [2,4]. VEGF is a key regulator of tumor angiogenesis,
inducing proliferation, differentiation, and migration of EC [45];
consequently numerous drugs have been developed to target its
function and its receptors [5]. Current strategies combining
antiangiogenic therapy with cytotoxic agents have shown proven
efficacy in cancer patients [46].
Figure 7. Effect of 5C3 on tumor growth in MiaPACA-2 xenograft model. A) Antitumor activity of 5C3. PBS (negative control) or 5C3 (25 mg/
kg) was given i.p. three times a week (1010100). At the end of the experiment, mice were sacrificed and tumors were weighted. Graphs of RTV shows
the activity of 5C3 compared with the control group. Bars of tumor weight show the mean 6 SEM. *p,0.05. B) Immunohistologic analysis of tumor
microvasculature from MiaPACA-2 tumors comparing PBS control group and animals treated whit 5C3. Box and whiskers graphs show the vascular
density in a defined tumor area (MVD) expressed as the mean of vascular profiles (v.p.) per mm2, and the quantification of vessel area in the tumor
(Aa). Quantifications were made from more than 10 pictures per slice at a magnification of X120 (2.4 mm2). Images were analyzed using the NIH
ImageJ software. Graphs show the mean 6 SEM. *p,0.05.
doi:10.1371/journal.pone.0072480.g007
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In this regard, and taken in consideration the limitations of
antiangiogenic therapies, the identification of new actors, as the
S100A4 protein, playing an important role not only at this stage
but also in other tumor processes such as invasion, tumor
inflammation, interaction between tumor cells and their microen-
vironment and the formation of metastatic niches, will give
promising strategies for cancer therapy [10].
Recently, the role of S100A4 in tumor-associated angiogenesis
as well as in EC migration has been suggested [8,9,47,48]
indicating that S100A4 could act in association with other
angiogenic factors to achieve responses both in vitro and in vivo.
Here, we further extend previous studies about the role played
by S100A4 in tumor angiogenesis and development, demonstrat-
ing that extracellular S100A4 blockade with a specific monoclonal
antibody: (i) inhibits angiogenesis in vitro by blocking EC migration
induced by the combination of S100A4 and VEGF; (ii) blocks the
production of active forms of MMP-9 induced by S100A4; (iii)
blocks the molecular interaction of S100A4 and the receptor
RAGE; and (iv) reduces tumor angiogenesis and tumor growth
in vivo in melanoma and pancreatic subcutaneous xenograft
models, giving insights into a new strategy to treat tumors.
An important finding of this study involves the role played by
S100A4 on cell motility and migration towards a stimulus, using
HUVEC as a model. Our data show that exogenous addition of
recombinant S100A4 increases cell migration by acting synergis-
tically with VEGF in a dose-dependent manner and that targeting
S100A4 with a specific mAb was able to inhibit this process.
In this context, we also explored the mechanism(s) by which this
effect could be achieved, taking as starting point the fact that other
S100 proteins (S100P, S100A12 and S100A14) stimulate cellular
activities via the activation of RAGE [49,50]. We addressed the
interaction of S100A4 with RAGE through different in vitro
approaches demonstrating that S100A4 elicited its activity by
interacting with RAGE in HUVEC as it does in other cell types
such as chondrocytes [51]. This conclusion is based on the
following observations: first, full length RAGE interacts at the
molecular level with S100A4 in a dose-dependent fashion in the
BIAcore. Second, the effects of S100A4 on HUVEC migration
correlate with its ability to activate the ERK 1/2 signaling
pathway and the nuclear translocation of the transcription factor
NF-kB, both associated to RAGE signaling. Further, Erk
phosphorylation is sustained, in accordance to the literature
[24]. And third, an anti-RAGE mAb or a peptide homologous to a
region of the extracellular domain IgV1 of RAGE (P3) abrogate
the combined migratory stimulus of S100A4 plus VEGF, as well as
the steps of cell signaling associated to RAGE. Altogether these
results showed that S100A4 acts through RAGE in HUVECs to
promote the migratory response.
Given that bFGF acts synergistically with VEGF through an
upregulation of KDR [35,37], we checked whether S100A4 could
play a similar role. Indeed, we demonstrated that S100A4 plus
VEGF led to a synergistic increase in KDR protein levels in
HUVEC, which provides a mechanistic explanation for the
observed migration. The blockade of KDR expression with an
anti-RAGE mAb provided additional evidences of the S100A4
mechanism of action.
At this point we considered that other factors could contribute
to the potentiation elicited by S100A4 on VEGF-induced
migration. Specifically, the ERK 1/2/NF-kB pathway has been
associated with the regulation of expression of MMPs in several
cell types [52,53,54], thus facilitating the degradation of the
extracellular matrix. Our work indicates that human S100A4
increases the production and secretion of highly active forms of
MMP-9, suggesting a relationship between MMPs activation and
the migratory effect of S100A4. Other authors using an
osteosarcoma cell line or chondrocytes observed a correlation
between S100A4 and MMP activation [38,51]. Therefore,
S100A4 could participate in controlling basal membrane degra-
dation of EC and in the destruction of the ECM to facilitate the
invasion of tumor cells.
This fact opens a mechanistic explanation for extracellular
S100A4 in which the increase on VEGF-induced migration in
HUVEC promoted by S100A4 would rely on a combined action
of an increase in KDR and the activation of MMPs through a
signaling pathway initiated by RAGE.
To extend the knowledge regarding the inhibitory capacity of
5C3 mAb on the in vitro activity of the extracellular S100A4
protein, we chose two different steps in its signaling pathway, the
molecular interaction with RAGE and the production of active
forms of MMP-9. In both cases we noted a blockade of S100A4
activity, suggesting the potential therapeutic role of our antibody.
There is a growing body of evidence that S100A4, like others
members of the S100 family, may play an important role in tumor
angiogenesis, tumor growth and cancer metastasis [55,56]. We
further sought to determine whether S100A4 has a critical role in
some animal tumor models.
Accordingly, we observed that S100A4 genetic transfer to a
melanoma cell line induced a significant increase on tumor growth
compared to its counterpart when cells were injected subcutane-
ously in athymic mice, while no differences were observed in cell
proliferation. Tumor angiogenesis analysis from these cells showed
a dramatic increase in vascularization, phenomenon that could
explain the role of secreted S100A4 by tumor cells, therefore
increasing in part the measured tumor growth. To further
determine the hypothesis that this effect was due in part by the
presence of extracellular S100A4, we treated animals bearing
tumors from cells overexpressing S100A4 with the 5C3 monoclo-
nal antibody, obtaining a remarkable reduction in tumor growth
and tumor angiogenesis, thus indicating the importance of S100A4
on tumor development and confirming that therapies using
antibodies against S100A4 can be promising strategies to treat
cancer.
In this line of in vivo evidences, we observed that the stable
silencing of S100A4 with shRNA in MiaPACA-2 cells dramatically
inhibited the tumor growth. This demonstrates on the one hand
the important role of S100A4 on tumor development and on the
other hand that silencing is more specific than overexpression for
determining the role of a factor in cell biology because the
problems associated with overexpression are avoided. Moreover,
the depletion of S100A4 by shRNA, which knocks down
intracellular and extracellular expression, demonstrates the
prominent role of the tumor cell in the crosstalk between tumor
and stromal cells. Thus, these results suggest that in a therapeutic
approach, it will be desirable to combine inhibitors for the
intracellular and extracelluar S100A4 activity. Next we wanted to
test the effectiveness of 5C3 mAb in blocking the extracellular role
of S100A4 in MiaPACA-2 cells. Our findings indicated that 5C3
regressed tumor vasculature and inhibited in part tumor growth,
pointing to a critical role of extracellular S100A4 during tumor
progression. Then, it is possible to think of therapeutic strategies
either as antiangiogenic, antitumoral or antimetastatic activities in
relation to the blockade of extracellular S100A4 protein alone or
in combination with other specific (e.g., anti-VEGF therapy) or
generic (e.g., chemotherapy) treatments.
In order to substantiate this hypothesis, we examined 5C39s
activity in combination with the chemotherapeutic agent Gemci-
tabine on MiaPACA-2 cells and determined the degree of synergy.
Our analysis showed a clear synergistic dose-response effect
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demonstrating an increase in the effectiveness of Gemcitabine
treatment and furthermore opening new rationales for combined
antitumor treatments.
Finally, based on the evidence that S100A4 is secreted by tumor
cells and tumor activated stromal cells [57,58,59], and that the
determination of S100A4 in plasma derived from cancer patients
is feasible [60], we extended the studies and analyzed the presence
of S100A4 in plasma from mice bearing tumors developed from
different human cell lines. Our data further indicate that S100A4
could be considered as a good plasmatic biomarker because it
allowed us to discriminate between animals with or without
tumors. Moreover we can broadly affirm that 5C3 mAb is a
valuable tool for use in diagnostic, and disease monitoring.
Taken all these observations together, we have elucidated a
therapeutic strategy by blocking extracellular S100A4 protein with
a first in class monoclonal antibody. This new drug alone or in
combination with antiangiogenic or chemotherapeutic agents
could be a critical inhibitory strategy to decrease tumor
vasculature and consequently inhibit tumor development. More-
over, it has also been demonstrated that S100A4 can be used for
monitoring treatment response and as a serum biomarker with
potential diagnostic value.
A more extensive knowledge of the proteins interacting with
S100A4 and the signaling pathways involved in tumor and EC,
will undoubtedly be a further step in understanding the process of
angiogenesis and metastasis. In the same direction, strategies
designed to block any step in the signaling induced by S100A4 in
tumor vasculature might represent potential approaches to tackle
tumor growth and dissemination, and hence a contribution to the
development of novel antitumoral and/or antiangiogenic thera-
pies.
Supporting Information
Figur e S1 S100A4 and RAGE expr ession levels. A)
Western-blot analysis of S100A4 and RAGE expression in M21
(mock vector and S100A4 overexpressed), MiaPACA-2 (mock
vector and S100A4 silenced) and HUVECs cells. B) RT-PCR
analysis of mRNA expression of S100A4 and RAGE. C) Secretion
levels of S100A4 protein of M21, MiaPACA-2 and HUVECs cells
determined by sandwich ELISA.
(TIF)
Figur e S2 S100A4 determ ina tion in p lasm a sam ples.
Plasma levels of S100A4 protein in several xenograft models in
athymic mice compared with S100A4 levels in animals without
tumor (no tumor) were determined by a sandwich ELISA method.
One human pancreatic adenocarcinoma cell line (MiaPACA-2),
two human colon adenocarcinoma cell lines (HCT116 and
Colo205) and one human breast adenocarcinoma cell line
(MDAMB231) were used for tumor growth. Plasma levels were
measured at the end of the experiment. Graph of plasma levels
shows the mean 6 SEM (n=10). **p,0.01, ***p,0.001.
(TIF)
Figur e S3 Cytotoxic effect of Gem citab ine com bined
with 5C3 mAb in MiaPACA-2 cells. The effect of Gemcita-
bine, alone or in combination with 5C3 mAb, on cell viability was
measured by hexosaminidase activity and BrdU incorporation. A)
Dose-response effect of Gemcitabine was improved synergistically
with the combination of 5C3 mAb. MiaPACA-2 cells were
incubated with the chemotherapeutic drug at different doses (from
5 mM to 2 nM, dil 1:3) with or without 5C3, at a constant
concentration of 40 nM or 100 nM, for 72 h. Percentage of
viability was determined in comparison to the positive control
(cells without compounds) that represents 100% viability. B) Effect
on proliferation for the combination of different doses of
Gemcitabine (from 5 mM to 2 nM, dil 1:3) with 5C3 at 40 nM
of 100 nM, along 72 h. The level of interaction (synergistic,
additive or antagonist effect) between Gemcitabine and 5C3 was
quantified by the combination index (CI): CI~ D� �1= Dm� �1
where (Dm)1 =EC50 Drug 1 concentration and (D)1=EC50
(Drug 1+ Drug 2). The error bars represent mean 6 SEM (n=6).
(TIF)
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